Use of chemotherapy and loco‐regional therapy in stage IA triple‐negative breast cancer and their association with oncologic outcomes: A cancer registry study
Authors:
- Baden‐Württemberg Cancer Registry (Bwcr)B(Baden‐Württemberg Cancer Registry (Bwcr)
- Philipp MorakisPMPhilipp Morakis
- 18 September 2024
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 156 (3) , 587-597
Abstract
We aimed to evaluate the role of adjuvant chemotherapy and loco‐regional therapy for stage IA (pT1, pN0) triple‐negative breast cancer (TNBC) in a real‐world setting. We identified patients with pT1, pN0 TNBC diagnosed between 2009 and 2021 within the Baden‐Württemberg cancer registry (BWCR), Germany. Overall survival (OS) was assessed using Kaplan–Meier statistics and multivariate Cox regression models (adjusted for age, use of chemotherapy, local therapy (breast conserving therapy [breast conserving surgery + radiotherapy] vs. mastectomy), and tumor histologic subtype). A total of 1231 patients with a median follow‐up of 45.9 months were identified: 1.0% (12 of 1231) with pT1mi stage, 9.5% (117 of 1231) with pT1a, 23.7% (292 of 1231) with pT1b, and 65.8% (810 of 1231) with pT1c. Multivariate Cox regression analysis revealed no significant influence for the use of chemotherapy on OS in pT1b patients (HR 0.90, 95% CI 0.43–1.90). For pT1c patients with Grade 1–2 tumors, the use of chemotherapy was not significantly associated OS (HR 1.01, 95% CI 0.48–2.11) but breast conserving therapy was associated with improved OS (HR 0.41, 95% CI 0.18–0.93). For pT1c patients with Grade 3 tumors, the use of chemotherapy (HR 0.51, 95% CI 0.33–0.78) as well as breast conserving therapy (HR 0.42, 95% CI 0.23–0.76) was associated with OS. This data suggests that OS in stage IA TNBC is strongly influenced by local therapy rather than the use of chemotherapy, except for pT1c patients with Grade 3 tumors. Larger studies with longer‐term follow‐up are welcomed to fully inform this discussion.Keywords
Funding Information
- Deutsches Krebsforschungszentrum
This publication has 11 references indexed in Scilit:
- Prognosis and trends in chemotherapy use for patients with stage IA triple-negative breast cancer (TNBC): A population-based study.Journal of Clinical Oncology, 2023
- Outcomes after breast-conserving surgery or mastectomy in patients with triple-negative breast cancer: meta-analysisBritish Journal of Surgery, 2021
- Association of Adjuvant Chemotherapy With Overall Survival Among Women With Small, Node-Negative, Triple-Negative Breast CancerJAMA Network Open, 2020
- Adjuvant chemotherapy in small node-negative triple-negative breast cancerEuropean Journal of Cancer, 2020
- Pembrolizumab for Early Triple-Negative Breast CancerNew England Journal of Medicine, 2020
- Update on triple‐negative breast cancer disparities for the United States: A population‐based study from the United States Cancer Statistics database, 2010 through 2014Cancer, 2019
- Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective studyEuropean Journal of Cancer, 2017
- Adjuvant Capecitabine for Breast Cancer after Preoperative ChemotherapyNew England Journal of Medicine, 2017
- Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast CancerNew England Journal of Medicine, 2002
- Twenty-Year Follow-up of a Randomized Study Comparing Breast-Conserving Surgery with Radical Mastectomy for Early Breast CancerNew England Journal of Medicine, 2002